Apremilast in Patients Difficult to Treat: A Multicentric Real-Life Long-Term Experience
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apremilast in Patients Difficult to Treat: A Multicentric Real-Life Long-Term Experience
Authors
Keywords
-
Journal
Dermatologic Therapy
Volume 2023, Issue -, Pages 1-7
Publisher
Hindawi Limited
Online
2023-10-31
DOI
10.1155/2023/9775738
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France
- (2023) Pauline Podevin et al. EUROPEAN JOURNAL OF DERMATOLOGY
- Psoriatic patients with a history of cancer: a real‐life experience with Apremilast treatment for 104 weeks
- (2022) Nicoletta Bernardini et al. Dermatologic Therapy
- Clinical Implication of Phosphodiesterase-4-Inhibition
- (2022) Martin Alexander Schick et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome
- (2022) Emanuele Trovato et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Apremilast in psoriasis patients with serious comorbidities: a case series and systematic review of literature
- (2022) Aikaterini Tsentemeidou et al. Dermatology Practical & Conceptual
- Comorbidities in psoriatic arthritis: a systematic review and meta-analysis
- (2021) Sonal Gupta et al. RHEUMATOLOGY INTERNATIONAL
- A multicentre open‐label study of apremilast in palmoplantar pustulosis (APLANTUS)
- (2021) D. Wilsmann‐Theis et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Long‐term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real‐world, single‐center experience
- (2021) Giulia Radi et al. Dermatologic Therapy
- Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast
- (2019) Davide Fattore et al. EUROPEAN JOURNAL OF CANCER
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis
- (2016) Mohn’d AbuHilal et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Prevalence of Psoriatic Arthritis in Primary Care Patients With Psoriasis
- (2016) Maren C. Karreman et al. Arthritis & Rheumatology
- The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases
- (2016) Verena Katharina Raker et al. Frontiers in Immunology
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis and uveitis: a literature review
- (2012) Naiara Abreu de Azevedo Fraga et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies
- (2012) A W Armstrong et al. Nutrition & Diabetes
- Psoriasis and Cardiovascular Risk: Strength in Numbers
- (2010) Joel M. Gelfand et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- HIV-associated psoriasis: pathogenesis, clinical features, and management
- (2010) Nilesh Morar et al. LANCET INFECTIOUS DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now